STOCK TITAN

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in the 11th Annual Immuno-Oncology 360° Conference 2025 in Boston, MA from March 24-26, 2025.

William Ho, CEO and co-founder, will serve as Co-Chair for Day 2 on March 25, leading key sessions including:

  • Welcome remarks and discussion on 'Tackling the Tough Questions in IO for Autoimmunity Disease' at 8:15 AM EDT
  • Chairing the 'State of the IO Market, Investments and Deals Plenary'
  • Presentation on 'Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager' at 4:35 PM EDT

The presentations will highlight IN8bio's recently announced INB-619 T cell engager program for oncology and autoimmune diseases, focusing on the potential of gamma-delta T cell engagers in addressing autoimmunity.

IN8bio (Nasdaq: INAB), un'azienda biofarmaceutica in fase clinica focalizzata sulle terapie con cellule T gamma-delta, ha annunciato la sua partecipazione alla 11ª Conferenza Annuale Immuno-Oncology 360° 2025 a Boston, MA, dal 24 al 26 marzo 2025.

William Ho, CEO e co-fondatore, sarà Co-Presidente per il Giorno 2, il 25 marzo, guidando sessioni chiave tra cui:

  • Osservazioni di benvenuto e discussione su 'Affrontare le Domande Difficili nell'IO per le Malattie Autoimmuni' alle 8:15 AM EDT
  • Presiedere la plenaria 'Stato del Mercato IO, Investimenti e Affari'
  • Presentazione su 'Scegliere il Nostro Cavallo nella Corsa per l'Autoimmunità: L'Engager di Cellule T Gamma-Delta' alle 4:35 PM EDT

Le presentazioni metteranno in evidenza il programma recentemente annunciato di INB-619, un engager di cellule T per l'oncologia e le malattie autoimmuni, concentrandosi sul potenziale degli engager di cellule T gamma-delta nell'affrontare l'autoimmunità.

IN8bio (Nasdaq: INAB), una empresa biofarmacéutica en etapa clínica centrada en terapias con células T gamma-delta, ha anunciado su participación en la 11ª Conferencia Anual Immuno-Oncology 360° 2025 en Boston, MA, del 24 al 26 de marzo de 2025.

William Ho, CEO y cofundador, será Co-Presidente del Día 2 el 25 de marzo, liderando sesiones clave que incluyen:

  • Comentarios de bienvenida y discusión sobre 'Abordando las Preguntas Difíciles en IO para Enfermedades Autoinmunes' a las 8:15 AM EDT
  • Presidir la plenaria 'Estado del Mercado IO, Inversiones y Acuerdos'
  • Presentación sobre 'Eligiendo Nuestro Caballo en la Carrera por la Autoinmunidad: El Engager de Células T Gamma-Delta' a las 4:35 PM EDT

Las presentaciones destacarán el programa de engager de células T INB-619 recientemente anunciado para oncología y enfermedades autoinmunes, centrándose en el potencial de los engagers de células T gamma-delta para abordar la autoinmunidad.

IN8bio (Nasdaq: INAB), 감마-델타 T 세포 치료에 집중하는 임상 단계의 생명공학 회사가 2025년 3월 24일부터 26일까지 매사추세츠주 보스턴에서 열리는 제11회 연례 면역종양학 360° 회의 2025에 참여한다고 발표했습니다.

CEO이자 공동 설립자인 William Ho는 3월 25일 2일 차의 공동 의장을 맡아 다음과 같은 주요 세션을 이끌 예정입니다:

  • '자가면역 질환을 위한 IO에서의 어려운 질문 다루기'에 대한 환영사 및 토론, 오전 8:15 EDT
  • 'IO 시장의 현황, 투자 및 거래' 총회 의장
  • '자가면역을 위한 경주에서 우리의 말을 고르기: 감마-델타 T 세포 인게이저'에 대한 발표, 오후 4:35 EDT

발표는 최근 발표된 ONB-619 T 세포 인게이저 프로그램을 강조하며, 자가면역 질환을 다루는 감마-델타 T 세포 인게이저의 잠재력에 초점을 맞출 것입니다.

IN8bio (Nasdaq: INAB), une entreprise biopharmaceutique en phase clinique axée sur les thérapies par cellules T gamma-delta, a annoncé sa participation à la 11e Conférence Annuelle Immuno-Oncology 360° 2025 à Boston, MA, du 24 au 26 mars 2025.

William Ho, PDG et co-fondateur, sera Co-Président pour le Jour 2 le 25 mars, dirigeant des sessions clés comprenant :

  • Discours de bienvenue et discussion sur 'Aborder les Questions Difficiles en IO pour les Maladies Auto-immunes' à 8h15 EDT
  • Présider la plénière 'État du Marché IO, Investissements et Accords'
  • Présentation sur 'Choisir notre Cheval dans la Course pour l'Auto-immunité : L'Engager de Cellules T Gamma-Delta' à 16h35 EDT

Les présentations mettront en lumière le programme récemment annoncé d'INB-619, un engager de cellules T pour l'oncologie et les maladies auto-immunes, en se concentrant sur le potentiel des engageurs de cellules T gamma-delta pour traiter l'auto-immunité.

IN8bio (Nasdaq: INAB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gamma-Delta-T-Zelltherapien konzentriert, hat seine Teilnahme an der 11. jährlichen Immuno-Oncology 360°-Konferenz 2025 in Boston, MA, vom 24. bis 26. März 2025 bekannt gegeben.

William Ho, CEO und Mitgründer, wird am 25. März als Co-Vorsitzender für den zweiten Tag fungieren und wichtige Sitzungen leiten, darunter:

  • Begrüßungsansprache und Diskussion über 'Die schwierigen Fragen in der IO für Autoimmunerkrankungen angehen' um 8:15 Uhr EDT
  • Vorsitz der Plenarsitzung 'Zustand des IO-Marktes, Investitionen und Deals'
  • Präsentation über 'Unser Pferd im Rennen um Autoimmunität auswählen: Der Gamma-Delta-T-Zell-Engager' um 16:35 Uhr EDT

Die Präsentationen werden das kürzlich angekündigte INB-619-T-Zell-Engager-Programm für Onkologie und Autoimmunerkrankungen hervorheben, wobei der Fokus auf dem Potenzial von Gamma-Delta-T-Zell-Engagern zur Bekämpfung von Autoimmunität liegt.

Positive
  • None.
Negative
  • None.

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that the Company will participate in multiple sessions at the Immuno-Oncology 360° (IO360°) Conference 2025, held March 24-26, 2025, in Boston, MA.

William Ho, Chief Executive Officer and co-founder of IN8bio, will be Co-Chairing Day 2 of the conference starting at 8:15 AM EDT on March 25, 2025. He will deliver the welcoming remarks and discuss, “Tackling the Tough Questions in IO for Autoimmunity Disease.” After, he will Chair the session, “State of the IO Market, Investments and Deals Plenary.”

During the afternoon session, at 4:35 PM EDT, Mr. Ho will present on the topic of “Picking our Horse in the Race for Autoimmunity: The Gamma-Delta T cell Engager,” and provide a corporate overview of IN8bio’s recently announced INB-619, T cell engager program for oncology and autoimmune diseases.

As co-chair and panelist, Mr. Ho expects to discuss the rationale and promise of a gamma-delta T cell engager in addressing autoimmunity, a rapidly emerging frontier for immunotherapies.

Presentation and Panel Details

Co-Chairs' Welcome & Tackling the Tough Questions in IO for Autoimmunity Disease

  • Date/Time: March 25, 2025, at 8:15 AM EDT

Picking Our Horse in the Race for Autoimmunity: The Gamma-Delta T Cell Engager

  • Date/Time: March 25, 2025, at 4:35 PM EDT

For those interested in coordinating a time to meet with the IN8bio during IO360°, please email glenn@z3bio.com.

For more information about the event, visit https://io360summit.com.

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma, and advancing novel gamma-delta T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.

Investors & Company Contacts:
Glenn Schulman, PharmD, MPH
203.494.7411
glenn@z3bio.com

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact:
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com


FAQ

What will IN8bio (INAB) present at the IO360° Conference 2025?

IN8bio will present their INB-619 T cell engager program and discuss gamma-delta T cell therapy applications in autoimmunity on March 25, 2025, with sessions at 8:15 AM and 4:35 PM EDT.

When and where is IN8bio (INAB) participating in the IO360° Conference 2025?

IN8bio is participating in the IO360° Conference from March 24-26, 2025, in Boston, MA, with CEO William Ho co-chairing Day 2 on March 25.

What is IN8bio's (INAB) new therapeutic program discussed at IO360°?

IN8bio will discuss INB-619, their T cell engager program targeting both oncology and autoimmune diseases, focusing on gamma-delta T cell therapy.

Which sessions will IN8bio's (INAB) CEO lead at IO360° 2025?

CEO William Ho will lead 'Tackling Tough Questions in IO for Autoimmunity Disease,' chair the 'State of IO Market' session, and present on gamma-delta T cell engagers.
In8Bio, Inc.

NASDAQ:INAB

INAB Rankings

INAB Latest News

INAB Stock Data

13.92M
72.48M
12.57%
36.96%
1.1%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEW YORK